Ancillary Medical Solutions

What Ancillary Medical Solutions does

Ancillary Medical Solutions is a privately held, San Diego-based medical device company founded in 2014 that develops and commercializes non-invasive pulsed radio frequency (PRF) treatment systems for chronic pain management. Its flagship product, the Stimpod NMS460, is positioned as the world's first non-invasive PRF system and uses a patented electromagnetic waveform delivered transcutaneously to affect the cellular metabolic activity of neuropathic nerves; the induced electromagnetic field propagates as short bursts along axons to the spinal dorsal horn, with the intent of restoring natural nerve functionality. The device carries labeled indications for symptomatic relief and management of chronic intractable pain, adjunctive treatment of post-surgical and post-traumatic acute pain, and pain control during rehabilitation. Supporting products include a standalone Diabetic Neuropathy Device, conductive gel, replacement electrodes, a third-generation replacement treatment probe, and a combo package bundling hardware with one hour of specialist training.

The company targets a horizontal segment of healthcare practitioners — chiropractors (DCs), medical doctors (MDs), and physical therapists (PTs) — and operates a sales-led go-to-market through three parallel channels: a global direct e-commerce storefront on its own website, a subscription-based distributor starter plan ($97/month) for channel partners, and direct practitioner sales generated from website contact-form inquiries. Revenue is generated primarily through one-time hardware sales ($9,995 for the DND, $13,995 for the Stimpod combo package), supplemented by recurring consumables revenue (gel, electrodes, replacement probes) and the distributor subscription. Marketing is executed through website content, a Doctor Resources page featuring practitioner testimonials and case studies, and product blog content rather than paid advertising.

The company operates with 51-100 employees and is led by President and CEO Michael Berg. Its disclosed capital history is extremely thin, with only a $30,000 funding round recorded in March 2014, indicating a bootstrapped operating model. There are no public disclosures of revenue, institutional investors, regulatory actions, mergers or acquisitions, or formal partnership agreements in the available data.

Name

Ancillary Medical Solutions

Legal name

Ancillary Medical Solutions

Website

https://ancillarymedsolutions.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Ancillary Medical Solutions is a San Diego-based medical device company selling the Stimpod NMS460, a non-invasive pulsed radio frequency system for chronic pain treatment. It targets chiropractors, doctors, and physical therapists via e-commerce, distributor networks, and direct sales.

Ownership category

akta.pro rank

Product category

Pain management medical devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Chronic pain management
• Medical device distribution
• Neuropathy treatment devices
• Pulsed radio frequency
• Pain relief equipment

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: One-time sale of Stimpod NMS460 and Diabetic Neuropathy Device to healthcare providers including DCs, MDs, and PTs. Primary revenue stream from hardware sales.
2. Training Services: Specialist training services offered to DCs, MDs and PTs for proper device operation. Offered as part of combo packages or standalone.
3. Consumables and Accessories: Recurring sales of consumable products including Conductive Treatment Gel, Electrodes packs, and Replacement Treatment Probes.
4. Distributor Subscriptions: Distributor Sign Up - Starter Plan at $97.00 provides subscription-based access to distribution network.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Ancillary Medical Solutions designs, sells, and supports the Stimpod NMS460, a non-invasive pulsed radio frequency treatment system using a patented waveform delivered transcutaneously to treat chronic intractable pain, post-surgical pain, post-traumatic acute pain, and rehabilitation pain. The portfolio also includes the Diabetic Neuropathy Device, conductive treatment gel, electrodes, replacement probes, specialist training, and a distributor subscription program for healthcare providers such as chiropractors, medical doctors, and physical therapists.

Product overview

Ancillary Medical Solutions offers a portfolio of medical devices centered on the Stimpod NMS460 platform, described as the world's first non-invasive pulsed radio frequency treatment system. The core product portfolio includes the Stimpod NMS460 and the Diabetic Neuropathy Device™, both designed for non-invasive nerve stimulation therapy. Supporting products include consumables (Conductive Treatment Gel, Electrodes), accessories (Replacement Treatment Probe), training services, and a distributor subscription program. The company positions the Stimpod NMS460 as the central technology with multiple complementary offerings in their product ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

• Stimpod NMS460 The Stimpod NMS460 is the company's core medical device — a non-invasive pulsed radio frequency treatment system delivered transcutaneously via a patented waveform that restores natural nerve functionality. It is sold to chiropractors, medical doctors, and physical therapists for use in clinical pain management.
• Diabetic Neuropathy Device The Diabetic Neuropathy Device is a standalone medical device for the symptomatic relief and management of chronic pain conditions, including diabetic neuropathy, sold to healthcare providers for one-time purchase at $9,995.00.
• Stimpod NMS460 + Training (1 hour) + DND Combo Package The Combo Package bundles the Stimpod NMS460 device, one hour of specialist training, and DND service together at a $13,995.00 one-time price, giving practitioners the device and onboarding in a single purchase.
• Conductive Treatment Gel (2x 8oz tubes) Conductive Treatment Gel is a consumable accessory sold in pairs of 8oz tubes at $19.00, used with the Stimpod NMS460 to facilitate transcutaneous delivery of the treatment waveform.
• Electrodes for Stimpod NMS460 – Pack of 40 Replacement electrodes for the Stimpod NMS460 device are sold as a pack of 40 units at $51.00, providing recurring consumable revenue for existing device owners.
• Replacement Treatment Probe for Stimpod NMS460 (3rd Generation) A third-generation replacement treatment probe for the Stimpod NMS460 system, sold at $195.00 to existing device customers needing to refresh or replace a worn probe.
• Distributor Sign Up - Starter Plan The Distributor Sign Up - Starter Plan is a $97.00 monthly subscription that authorizes third-party distributors to resell the Stimpod NMS460 and related products to healthcare providers.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• SPR Therapeutics: Developer of the SPRINT PNS peripheral nerve stimulation system for chronic and post-surgical pain. Direct peer in nerve-targeted pain neuromodulation, though SPR's approach is minimally invasive versus Stimpod's non-invasive PRF.
• Nevro: Medical device company commercializing HF10 high-frequency spinal cord stimulation for chronic pain. Direct peer in neuromodulation-based chronic pain therapy, though Nevro is implanted vs. Stimpod's transcutaneous delivery.
• NeuroMetrix: Public neuromodulation medical device company focused on non-invasive nerve stimulation for chronic pain (e.g., Quell). Comparable to Ancillary Medical Solutions in offering non-invasive electrotherapeutic devices for neuropathic and chronic pain conditions to clinicians and consumers.
• RS Medical: Markets therapeutic and pain management electrotherapy devices used by chiropractors and physical therapists. Highly comparable specialty-channel focus on DCs and PTs for chronic and acute musculoskeletal pain.
• Zynex Medical: Sells electrotherapy and NMES/TENS devices for pain management and rehabilitation through a sales-led motion to clinics and providers. Closely comparable business model (device sales + clinician-focused GTM) and overlapping indications (chronic pain, post-surgical rehabilitation).

Broad incumbents

• Medtronic: Global medtech incumbent with a large Pain Therapies neuromodulation portfolio (spinal cord stimulators, targeted drug delivery, Vanta RC). Broader but overlapping competitor in pain neuromodulation serving many of the same clinical specialists.
• Boston Scientific: Markets the Spectra WaveWriter and other WaveWriter spinal cord stimulator systems for chronic pain. Broad incumbent competitor that anchors the standard of care in implanted neuromodulation, against which non-invasive PRF must demonstrate clinical and economic superiority.
• Abbott: Major incumbent with Proclaim DRG and Eterna spinal cord stimulation systems for chronic pain. Indirectly competes for clinician adoption budgets in pain management and represents the scale competitor any neuromodulation entrant must outperform on evidence and economics.

Emerging players

• BioElectronics Corporation: Sells ActiPatch and RecoveryRx devices that use pulsed electromagnetic/shortwave therapy for pain management. Comparable as an emerging non-invasive, drug-free pain device brand competing for clinician shelf space.
• Electrocore: Developer of gammaCore non-invasive vagus nerve stimulation for headache and pain indications. Comparable as an emerging non-invasive, prescription-style neuromodulation company targeting clinician prescribers with cleared pain indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks2 records

Key highlights5 records

Customer concentration

• Xx.com/AncillaryMed
• LinkedInlinkedin.com/company/ancillary-medical-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ancillary Medical Solutions